{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1258860\" title=\"THE MAIN PATHOGENS CAUSING FEBRILE ILLNESS AND IMPLICATIONS FOR FEVER MANAGEMENT IN LAOS; RESULTS FROM THE FIEBRE STUDY\" class=\"state-synced\">THE MAIN PATHOGENS CAUSING FEBRILE ILLNESS AND IMPLICATIONS FOR FEVER MANAGEMENT IN LAOS; RESULTS FROM THE FIEBRE STUDY</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1258861\" title=\"ETIOLOGY OF FEBRILE NEUROLOGICAL SYNDROMES IN LOW- AND MIDDLE-INCOME COUNTRIES: RESULTS FROM THE FIEBRE STUDY\" class=\"state-synced\">ETIOLOGY OF FEBRILE NEUROLOGICAL SYNDROMES IN LOW- AND MIDDLE-INCOME COUNTRIES: RESULTS FROM THE FIEBRE STUDY</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1258944\" title=\"DEVELOPMENT AND PERFORMANCE EVALUATION OF A LOW-COST, HIGH THROUGHPUT, MULTIPLEX IMMUNOASSAY OF THIRTEEN FEVER SEVERITY AND ETIOLOGY MARKERS\" class=\"state-synced\">DEVELOPMENT AND PERFORMANCE EVALUATION OF A LOW-COST, HIGH THROUGHPUT, MULTIPLEX IMMUNOASSAY OF THIRTEEN FEVER SEVERITY AND ETIOLOGY MARKERS</a>\n            </h4>\n            \n            \n            \n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1248659\" title=\"IgM seroneutralisation for improved confirmation of Japanese encephalitis virus infection in a flavivirus endemic area\" class=\"state-synced\">IgM seroneutralisation for improved confirmation of Japanese encephalitis virus infection in a flavivirus endemic area</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Background: The mainstay of diagnostic confirmation of acute Japanese encephalitis (JE) involves detection of anti-JEV IgM by ELISA. Limitations in the specificity of this test are increasingly apparent with the introduction of JEV vaccinations and the endemicity of other cross-reactive flaviviruses. Virus neutralisation testing (VNT) is considered the gold standard but is challenging to implement and interpret. We performed a pilot study to assess IgG depletion prior to VNT for detection of anti-JEV IgM neutralising antibodies, 'IgM-VNT' as compared to standard VNT.\nMethods: We evaluated IgM-VNT in paired sera from anti-JEV IgM ELISA positive patients (JE n=35) and negative controls of healthy flavivirus na\u00efve (n=10) as well as confirmed dengue (n=12) and Zika virus (n=4) patient sera. IgM-VNT was subsequently performed on single sera from additional JE patients (n=76).\nResults: Anti-JEV IgG was detectable in admission serum of 58% of JE patients. The positive, negative and overall percentage agreement (PPA, NPA, OPA) of IgM-VNT was 100%. 12/14 (86%) patient samples unclassified by VNT, and with sufficient sample available for IgG depletion and IgG ELISA confirming depletion were classified by IgM-VNT. IgM-VNT enabled JE case classification in 72/76 (95%) of the patients for whom only a single sample was available.\nConclusions: The novel approach has been readily adapted for high-throughput testing of single patient samples, and it holds promise for incorporation into algorithms for use in reference centres.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1259583\" title=\"Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014-2018: A cohort study.\" class=\"state-synced\">Incidence of chikungunya virus infections among Kenyan children with neurological disease, 2014-2018: A cohort study.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">BackgroundNeurological complications due to chikungunya virus (CHIKV) infection have been described in different parts of the world, with children being disproportionately affected. However, the burden of CHIKV-associated neurological disease in Africa is currently unknown and given the lack of diagnostic facilities in routine care it is possible that CHIKV is an unrecognized etiology among children with encephalitis or other neurological illness.Methods and findingsWe estimated the incidence of CHIKV infection among children hospitalized with neurological disease in Kilifi County, coastal Kenya. We used reverse transcriptase polymerase chain reaction (RT-PCR) to systematically test for CHIKV in cerebrospinal fluid (CSF) samples from children aged &lt;16 years hospitalized with symptoms of neurological disease at Kilifi County Hospital between January 2014 and December 2018. Clinical records were linked to the Kilifi Health and Demographic Surveillance System and population incidence rates of CHIKV infection estimated. There were 18,341 pediatric admissions for any reason during the 5-year study period, of which 4,332 (24%) had CSF collected. The most common clinical reasons for CSF collection were impaired consciousness, seizures, and coma (47%, 22%, and 21% of all collections, respectively). After acute investigations done for immediate clinical care, CSF samples were available for 3,980 admissions, of which 367 (9.2%) were CHIKV RT-PCR positive. Case fatality among CHIKV-positive children was 1.4% (95% CI 0.4, 3.2). The annual incidence of CHIKV-associated neurological disease varied between 13 to 58 episodes per 100,000 person-years among all children &lt;16 years old. Among children aged &lt;5 years, the incidence of CHIKV-associated neurological disease was 77 per 100,000 person-years, compared with 20 per 100,000 for cerebral malaria and 7 per 100,000 for bacterial meningitis during the study period. Because of incomplete case ascertainment due to children not presenting to hospital, or not having CSF collected, these are likely minimum estimates. Study limitations include reliance on hospital-based surveillance and limited CSF sampling in children in coma or other contraindications to lumbar puncture, both of which lead to under-ascertainment of incidence and of case fatality.ConclusionsIn this study, we observed that CHIKV infections are relatively more common than cerebral malaria and bacterial meningitis among children hospitalized with neurological disease in coastal Kenya. Given the wide distribution of CHIKV mosquito vectors, studies to determine the geographic extent of CHIKV-associated neurological disease in Africa are essential.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1244079\" title=\"Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data\" class=\"state-synced\">Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Abstract\nBackground\nPlasmodium falciparum malaria is associated with anaemia-related morbidity, attributable to host, parasite and drug factors. We quantified the haematological response following treatment of uncomplicated P. falciparum malaria to identify the factors associated with malarial anaemia.\n\nMethods\nIndividual patient data from eligible antimalarial efficacy studies of uncomplicated P. falciparum malaria, available through the WorldWide Antimalarial Resistance Network data repository prior to August 2015, were pooled using standardised methodology. The haematological response over time was quantified using a multivariable linear mixed effects model with nonlinear terms for time, and the model was then used to estimate the mean haemoglobin at day of nadir and day 7. Multivariable logistic regression quantified risk factors for moderately severe anaemia (haemoglobin &lt; 7 g/dL) at day 0, day 3 and day 7 as well as a fractional fall \u2265 25% at day 3 and day 7.\n\nResults\nA total of 70,226 patients, recruited into 200 studies between 1991 and 2013, were included in the analysis: 50,859 (72.4%) enrolled in Africa, 18,451 (26.3%) in Asia and 916 (1.3%) in South America. The median haemoglobin concentration at presentation was 9.9 g/dL (range 5.0\u201319.7 g/dL) in Africa, 11.6 g/dL (range 5.0\u201320.0 g/dL) in Asia and 12.3 g/dL (range 6.9\u201317.9 g/dL) in South America. Moderately severe anaemia (Hb &lt; 7g/dl) was present in 8.4% (4284/50,859) of patients from Africa, 3.3% (606/18,451) from Asia and 0.1% (1/916) from South America. The nadir haemoglobin occurred on day 2 post treatment with a mean fall from baseline of 0.57 g/dL in Africa and 1.13 g/dL in Asia. Independent risk factors for moderately severe anaemia on day 7, in both Africa and Asia, included moderately severe anaemia at baseline (adjusted odds ratio (AOR) = 16.10 and AOR = 23.00, respectively), young age (age &lt; 1 compared to \u2265 12 years AOR = 12.81 and AOR = 6.79, respectively), high parasitaemia (AOR = 1.78 and AOR = 1.58, respectively) and delayed parasite clearance (AOR = 2.44 and AOR = 2.59, respectively). In Asia, patients treated with an artemisinin-based regimen were at significantly greater risk of moderately severe anaemia on day 7 compared to those treated with a non-artemisinin-based regimen (AOR = 2.06 [95%CI 1.39\u20133.05], p &lt; 0.001).\n\nConclusions\nIn patients with uncomplicated P. falciparum malaria, the nadir haemoglobin occurs 2 days after starting treatment. Although artemisinin-based treatments increase the rate of parasite clearance, in Asia they are associated with a greater risk of anaemia during recovery.\n</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1259479\" title=\"The European &amp; Developing Countries Clinical Trials Partnership (EDCTP) Knowledge Hub: developing an open platform for facilitating high-quality clinical research.\" class=\"state-synced\">The European &amp; Developing Countries Clinical Trials Partnership (EDCTP) Knowledge Hub: developing an open platform for facilitating high-quality clinical research.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">There is stark global inequity in health research in terms of where studies happen, who leads the research and the ultimate beneficiaries of the results generated. Despite significant efforts made, limited research ideas are conceptualised and implemented in low-resource settings to tackle diseases of poverty, and this is especially true in sub-Saharan Africa. There is strong evidence to show that the barriers to locally led research do not vary largely between disease, study type and location and can be largely solved by addressing these common gaps. The European &amp; Developing Countries Clinical Trials Partnership (EDCTP) was established in 2003 as a European response to the global health crisis caused by the three main poverty-related diseases HIV, tuberculosis and malaria. EDCTP has established a model of long-term sustainable capacity development integrated into clinical trials which addresses this lack of locally led research in sub-Saharan Africa, supporting the development of individual and institutional capacity and research outputs that change the management, prevention and treatment of poverty-related and neglected infectious diseases across Africa. In recognition of emergent data on what the barriers and enablers are to long-term, sustainable capabilities to run studies, EDCTP formed a new collaboration with The Global Health Network (TGHN) in September 2017, with the aim to make a set of cross-cutting tools and resources to support the planning, writing and delivery of high-quality clinical trials available to research staff wherever they are in the world, especially those in low- and middle-income countries (LMICs) via TGHN platform. These new resources developed on the 'EDCTP Knowledge Hub' are those identified in the mixed method study described in this commentary as being key to addressing the gaps that the research community report as the most limiting elements in their ability to design and implement studies. The Knowledge Hub aims to make these tools freely available to any potential health research team in need of support and guidance in designing and running their own studies, particularly in low-resource settings. The purpose is to provide open access to the specific guidance, information and tools these teams cannot otherwise access freely. Ultimately, this will enable them to design and lead their own high-quality studies addressing local priorities with global alignment, generating new data that can change health outcomes in their communities.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1180213\" title=\"Effect of Delays in Concordant Antibiotic Treatment on Mortality in Patients With Hospital-Acquired Acinetobacter Species Bacteremia: Emulating a Target Randomized Trial With a 13-Year Retrospective Cohort.\" class=\"state-synced\">Effect of Delays in Concordant Antibiotic Treatment on Mortality in Patients With Hospital-Acquired Acinetobacter Species Bacteremia: Emulating a Target Randomized Trial With a 13-Year Retrospective Cohort.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Delays in treating bacteremias with antibiotics to which the causative organism is susceptible are expected to adversely affect patient outcomes. Quantifying the impact of such delays to concordant treatment is important for decision-making about interventions to reduce the delays and for quantifying the burden of disease due to antimicrobial resistance. There are, however, potentially important biases to be addressed, including immortal time bias. We aimed to estimate the impact of delays in appropriate antibiotic treatment of patients with Acinetobacter species hospital-acquired bacteremia in Thailand on 30-day mortality by emulating a target trial using retrospective cohort data from Sunpasitthiprasong Hospital in 2003-2015. For each day, we defined treatment as concordant if the isolated organism was susceptible to at least 1 antibiotic given. Among 1,203 patients with Acinetobacter species hospital-acquired bacteremia, 682 had 1 or more days of delays to concordant treatment. Surprisingly, crude 30-day mortality was lower in patients with delays of \u22653 days compared with those who had 1-2 days of delays. Accounting for confounders and immortal time bias resolved this paradox. Emulating a target trial, we found that these delays were associated with an absolute increase in expected 30-day mortality of 6.6% (95% confidence interval: 0.2, 13.0), from 33.8% to 40.4%.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1178171\" title=\"AMR in low-resource settings: M\u00e9decins Sans Fronti\u00e8res bridges surveillance gaps by developing a turnkey solution, the Mini-Lab.\" class=\"state-synced\">AMR in low-resource settings: M\u00e9decins Sans Fronti\u00e8res bridges surveillance gaps by developing a turnkey solution, the Mini-Lab.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">BackgroundIn low- and middle-income countries (LMICs), data related to antimicrobial resistance (AMR) are often inconsistently collected. Humanitarian, private and non-governmental medical organizations (NGOs), working with or in parallel to public medical systems, are sometimes present in these contexts. Yet, what is the role of NGOs in the fight against AMR, and how can they contribute to AMR data collection in contexts where reporting is scarce? How can context-adapted, high-quality clinical bacteriology be implemented in remote, challenging and underserved areas of the world?ObjectivesThe aim was to provide an overview of AMR data collection challenges in LMICs and describe one initiative, the Mini-Lab project developed by M\u00e9decins Sans Fronti\u00e8res (MSF), that attempts to partially address them.SourcesWe conducted a literature review using PubMed and Google scholar databases to identify peer-reviewed research and grey literature from publicly available reports and websites.ContentWe address the necessity of and difficulties related to obtaining AMR data in LMICs, as well as the role that actors outside of public medical systems can play in the collection of this information. We then describe how the Mini-Lab can provide simplified bacteriological diagnosis and AMR surveillance in challenging settings.ImplicationsNGOs are responsible for a large amount of healthcare provision in some very low-resourced contexts. As a result, they also have a role in AMR control, including bacteriological diagnosis and the collection of AMR-related data. Actors outside the public medical system can actively contribute to implementing and adapting clinical bacteriology in LMICs and can help improve AMR surveillance and data collection.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1239803\" title=\"Neisseria gonorrhoeae FC428 Subclone, Vietnam, 2019-2020.\" class=\"state-synced\">Neisseria gonorrhoeae FC428 Subclone, Vietnam, 2019-2020.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Among 114 clinical Neisseria gonorrhoeae isolates collected in Vietnam during 2019-2020, we detected 15 of subclone sequence type 13871 of the FC428 clonal complex. Fourteen sequence type 13871 isolates with mosaic penA allele 60.001 were ceftriaxone or cefixime nonsusceptible, and 3/14 were azithromycin nonsusceptible. Emergence of this subclone threatens treatment effectiveness.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1169786\" title=\"Family, social and cultural determinants of long-lasting insecticidal net (LLIN) use in Madagascar: secondary analysis of three qualitative studies focused on children aged 5-15\u00a0years.\" class=\"state-synced\">Family, social and cultural determinants of long-lasting insecticidal net (LLIN) use in Madagascar: secondary analysis of three qualitative studies focused on children aged 5-15\u00a0years.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">BackgroundAlthough it is accepted that long-lasting insecticidal net (LLIN) use is an effective means to prevent malaria, children aged 5 to 15\u00a0years do not appear to be sufficiently protected in Madagascar; the malaria prevalence is highest in this age group. The purpose of this research is to summarize recent qualitative studies describing LLIN use among the Malagasy people with a focus on children aged 5-15\u00a0years.MethodsQualitative data from three studies on malaria conducted between 2012 and 2016 in 10 districts of Madagascar were analysed. These studies cover all malaria epidemiological profiles and 10 of the 18 existing ethnic groups in Madagascar. A thematic analysis was conducted on the collected data from semi-structured interviews, direct observation data, and informal interviews.ResultsA total of 192 semi-structured interviews were conducted. LLINs are generally perceived positively because they protect the health and well-being of users. However, regional representations of mosquito nets may contribute to LLIN lower use by children over 5\u00a0years of age including the association between married status and LLIN use, which leads to the refusal of unmarried young men to sleep under LLINs; the custom of covering the dead with a mosquito net, which leads to fear of LLIN use; and taboos governing sleeping spaces for siblings of opposite sexes, which leads to LLIN shortages in households. Children under 5\u00a0years of age are known to be the most vulnerable age group for acquiring malaria and, therefore, are prioritized for LLIN use when there are limited supplies in households. In contrast, children over 5\u00a0years of age, who are perceived to be at less risk for malaria, often sleep without LLINs.ConclusionsPerceptions, social practices and regional beliefs regarding LLINs and vulnerability to malaria contribute to the nonuse of LLINs among children over 5\u00a0years of age in Madagascar. Modifying LLIN policies to account for these factors may increase LLIN use in this age group and reduce disease burden.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1239802\" title=\"Biphasic versus monophasic manual blood culture bottles for low-resource settings: an in-vitro study\" class=\"state-synced\">Biphasic versus monophasic manual blood culture bottles for low-resource settings: an in-vitro study</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Background: Manual blood culture bottles (BCBs) are frequently used in low-resource settings. There are few BCB performance evaluations, especially evaluations comparing them with automated systems. We evaluated two manual BCBs (Bi-State BCB and BacT/ALERT BCB) and compared their yield and time to growth detection with those of automated BacT/ALERT system. Methods: BCBs were spiked in triplicate with 177 clinical isolates representing pathogens common in low-resource settings (19 bacterial and one yeast species) in adult and paediatric volumes, resulting in 1056 spiked BCBs per BCB system. Growth in manual BCBs was evaluated daily by visually inspecting the broth, agar slant, and, for BacT/ALERT BCB, colour change of the growth indicator. The primary outcomes were BCB yield (proportion of spiked BCB showing growth) and time to detection (proportion of positive BCB with growth detected on day 1 of incubation). 95% CI for yield and growth on day 1 were calculated using bootstrap method for clustered data using. Secondary outcomes were time to colony for all BCBs (defined as number of days between incubation and colony growth sufficient to use for further testing) and difference between time to detection in broth and on agar slant for the Bi-State BCBs. Findings: Overall yield was 95\u00b79% (95% CI 93\u00b79\u201398\u00b70) for Bi-State BCB and 95\u00b75% (93\u00b73\u201397\u00b78) for manual BacT/ALERT, versus 96\u00b71% (94\u00b70\u201398\u00b71) for the automated BacT/ALERT system (p=0\u00b761). Day 1 growth was present in 920 (90\u00b78%) of 1013 positive Bi-State BCB and 757 (75\u00b70%) of 1009 positive manual BacT/ALERT BCB, versus 1008 (99\u00b73%) of 1015 automated bottles. On day 2, detection rates were 100% for BI-State BCB, 97\u00b77% for manual BacT/ALERT BCB, and 100% for automated bottles. For Bi-State BCB, growth mostly occurred simultaneously in broth and slant (81\u00b77%). Sufficient colony growth on the slant to perform further tests was present in only 44\u00b71% of biphasic bottles on day 2 and 59\u00b70% on day 3. Interpretation: The yield of manual BCB was comparable with the automated system, suggesting that manual blood culture systems are an acceptable alternative to automated systems in low-resource settings. Bi-State BCB outperformed manual BacT/ALERT bottles, but the agar slant did not allow earlier detection nor earlier colony growth. Time to detection for manual blood culture systems still lags that of automated systems, and research into innovative and affordable methods of growth detection in manual BCBs is encouraged. Funding: M\u00e9decins Sans Fronti\u00e8res and Department of Economy, Science and Innovation of the Flemish Government.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1200156\" title=\"COVID-19 transmission dynamics underlying epidemic waves in Kenya.\" class=\"state-synced\">COVID-19 transmission dynamics underlying epidemic waves in Kenya.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">[Figure: see text].</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1256343\" title=\"Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya.\" class=\"state-synced\">Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Background: There are limited studies in Africa describing the epidemiology, clinical characteristics and serostatus of individuals tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We tested routine samples from the Coastal part of Kenya between 17 th March 2020 and 30 th June 2021. Methods: SARS-CoV-2 infections identified using reverse transcription polymerase chain reaction (RT-PCR) and clinical surveillance data at the point of sample collection were used to classify as either symptomatic or asymptomatic. IgG antibodies were measured in sera samples, using a well validated in-house enzyme-linked immunosorbent assay (ELISA). Results: Mombasa accounted for 56.2% of all the 99,694 naso-pharyngeal/oro-pharyngeal swabs tested, and males constituted the majority tested (73.4%). A total of 7737 (7.7%) individuals were SARS-CoV-2 positive by RT-PCR. The majority (i.e., 92.4%) of the RT-PCR positive individuals were asymptomatic. Testing was dominated by mass screening and travellers, and even at health facility level 91.6% of tests were from individuals without symptoms. Out of the 97,124 tests from asymptomatic individuals 7,149 (7%) were positive and of the 2,568 symptomatic individuals 588 (23%) were positive. In total, 2458 serum samples were submitted with paired naso-pharyngeal/oro-pharyngeal samples and 45% of the RT-PCR positive samples and 20% of the RT-PCR negative samples were paired with positive serum samples. Symptomatic individuals had significantly higher antibody levels than asymptomatic individuals and become RT-PCR negative on repeat testing earlier than asymptomatic individuals. Conclusions: In conclusion, the majority of SARS-CoV-2 infections identified by routine testing in Coastal Kenya were asymptomatic. This reflects the testing practice of health services in Kenya, but also implies that asymptomatic infection is very common in the population. Symptomatic infection may be less common, or it may be that individuals do not present for testing when they have symptoms.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1248750\" title=\"Targeted Amplicon Deep Sequencing for Monitoring Antimalarial Resistance Markers in Western Kenya.\" class=\"state-synced\">Targeted Amplicon Deep Sequencing for Monitoring Antimalarial Resistance Markers in Western Kenya.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Molecular surveillance of Plasmodium falciparum parasites is important to track emerging and new mutations and trends in established mutations and should serve as an early warning system for antimalarial resistance. Dried blood spots were obtained from a Plasmodium falciparum malaria survey in school children conducted across eight counties in western Kenya in 2019. Real-time PCR identified 500 P. falciparum-positive samples that were amplified at five drug resistance loci for targeted amplicon deep sequencing (TADS). The absence of important kelch 13 mutations was similar to previous findings in Kenya pre-2019, and low-frequency mutations were observed in codons 569 and 578. The chloroquine resistance transporter gene codons 76 and 145 were wild type, indicating that the parasites were chloroquine and piperaquine sensitive, respectively. The multidrug resistance gene 1 haplotypes based on codons 86, 184, and 199 were predominantly present in mixed infections with haplotypes NYT and NFT, driven by the absence of chloroquine pressure and the use of lumefantrine, respectively. The sulfadoxine-pyrimethamine resistance profile was a \"superresistant\" combination of triple mutations in both Pfdhfr (51I 59R 108N) and Pfdhps (436H 437G 540E), rendering sulfadoxine-pyrimethamine ineffective. TADS highlighted the low-frequency variants, allowing the early identification of new mutations, Pfmdr1 codon 199S and Pfdhfr codon 85I and emerging 164L mutations. The added value of TADS is its accuracy in identifying mixed-genotype infections and for high-throughput monitoring of antimalarial resistance markers.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1198377\" title=\"Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination.\" class=\"state-synced\">Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">ObjectivesAntibody function has been extensively studied in HIV-infected adults but is relatively understudied in children. Emerging data suggests enhanced development of broadly neutralizing antibodies (bNAbs) in children but Fc effector functions in this group are less well defined. Here, we profiled overall antibody function in HIV-infected children.DesignPlasma samples from a cross-sectional study of 50 antiretroviral therapy-naive children (aged 1-11\u200ayears) vertically infected with HIV-1 clade A were screened for HIV-specific binding antibody levels and neutralizing and Fc-mediated functions.MethodsNeutralization breadth was determined against a globally representative panel of 12 viruses. HIV-specific antibody levels were determined using a multiplex assay. Fc-mediated antibody functions measured were antibody-dependent: cellular phagocytosis (ADCP); neutrophil phagocytosis (ADNP); complement deposition (ADCD) and natural killer function (ADNK).ResultsAll children had HIV gp120-specific antibodies, largely of the IgG1 subtype. Fifty-four percent of the children exhibited more than 50% neutralization breadth, with older children showing significantly broader neutralization activity. Apart from ADCC, observed only in 16% children, other Fc-mediated functions were common (&gt;58% children). Neutralization breadth correlated with Fc-mediated functions suggesting shared determinants of enhanced antibody function exist.ConclusionsThese results are consistent with previous observations that children may develop high levels of neutralization breadth. Furthermore, the striking association between neutralization breadth and Fc effector function suggests that HIV vaccination in children could yield multifunctional antibodies. Paediatric populations may therefore provide an ideal window of opportunity for HIV vaccination strategies.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1255590\" title=\"Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.\" class=\"state-synced\">Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study.</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">COVID-19 is clinically characterised by fever, cough, and dyspnoea. Symptoms affecting other organ systems have been reported. However, it is the clinical associations of different patterns of symptoms which influence diagnostic and therapeutic decision-making. In this study, we applied clustering techniques to a large prospective cohort of hospitalised patients with COVID-19 to identify clinically meaningful sub-phenotypes. We obtained structured clinical data on 59,011 patients in the UK (the ISARIC Coronavirus Clinical Characterisation Consortium, 4C) and used a principled, unsupervised clustering approach to partition the first 25,477 cases according to symptoms reported at recruitment. We validated our findings in a second group of 33,534 cases recruited to ISARIC-4C, and in 4,445 cases recruited to a separate study of community cases. Unsupervised clustering identified distinct sub-phenotypes. First, a core symptom set of fever, cough, and dyspnoea, which co-occurred with additional symptoms in three further patterns: fatigue and confusion, diarrhoea and vomiting, or productive cough. Presentations with a single reported symptom of dyspnoea or confusion were also identified, alongside a sub-phenotype of patients reporting few or no symptoms. Patients presenting with gastrointestinal symptoms were more commonly female, had a longer duration of symptoms before presentation, and had lower 30-day mortality. Patients presenting with confusion, with or without core symptoms, were older and had a higher unadjusted mortality. Symptom sub-phenotypes were highly consistent in replication analysis within the ISARIC-4C study. Similar patterns were externally verified in patients from a study of self-reported symptoms of mild disease. The large scale of the ISARIC-4C study enabled robust, granular discovery and replication. Clinical interpretation is necessary to determine which of these observations have practical utility. We propose that four sub-phenotypes are usefully distinct from the core symptom group: gastro-intestinal disease, productive cough, confusion, and pauci-symptomatic presentations. Importantly, each is associated with an in-hospital mortality which differs from that of patients with core symptoms.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1141396\" title=\"Genetic surveillance in the Greater Mekong Subregion and South Asia to support malaria control and elimination\" class=\"state-synced\">Genetic surveillance in the Greater Mekong Subregion and South Asia to support malaria control and elimination</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">ABSTRACTNational Malaria Control Programmes (NMCPs) currently make limited use of parasite genetic data. We have developed GenRe-Mekong, a platform for genetic surveillance of malaria in the Greater Mekong Subregion (GMS) that enables NMCPs to implement large-scale surveillance projects by integrating simple sample collection procedures in routine public health procedures. Samples are processed by high-throughput technologies to genotype several drug resistance markers, species markers and a genomic barcode, delivering reports of genotypes and phenotype predictions, used to map prevalence of resistance to multiple drugs. GenRe-Mekong has worked with NMCPs and research projects in eight countries, processing 9,623 samples from clinical cases. Monitoring resistance markers has been valuable for tracking the rapid spread of parasites resistant to the dihydroartemisinin-piperaquine combination therapy. In Vietnam and Laos, GenRe-Mekong data have provided novel knowledge about the spread of these resistant strains into previously unaffected provinces. GenRe-Mekong facilitates data sharing by aggregating results from different countries, enabling cross-border resistance monitoring.Impact StatementLarge-scale genetic surveillance of malaria implemented by National Malaria Control Programmes informs public health decision makers about the spread of strains resistant to antimalarials.FundingBill &amp; Melinda Gates Foundation, Wellcome Trust, UK Medical Research Council, UK Department for International Development, NIAID</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1237749\" title=\"Plasmodium falciparum parasite prevalence in East Africa: Updating data for malaria stratification\" class=\"state-synced\">Plasmodium falciparum parasite prevalence in East Africa: Updating data for malaria stratification</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">The High Burden High Impact (HBHI) strategy for malaria encourages countries to use multiple sources of available data to define the sub-national vulnerabilities to malaria risk, including parasite prevalence. Here, a modelled estimate of Plasmodium falciparum from an updated assembly of community parasite survey data in Kenya, mainland Tanzania, and Uganda is presented and used to provide a more contemporary understanding of the sub-national malaria prevalence stratification across the sub-region for 2019. Malaria prevalence data from surveys undertaken between January 2010 and June 2020 were assembled form each of the three countries. Bayesian spatiotemporal model-based approaches were used to interpolate space-time data at fine spatial resolution adjusting for population, environmental and ecological covariates across the three countries. A total of 18,940 time-space age-standardised and microscopy-converted surveys were assembled of which 14,170 (74.8%) were identified after 2017. The estimated national population-adjusted posterior mean parasite prevalence was 4.7% (95% Bayesian Credible Interval 2.6\u201336.9) in Kenya, 10.6% (3.4\u201339.2) in mainland Tanzania, and 9.5% (4.0\u201348.3) in Uganda. In 2019, more than 12.7 million people resided in communities where parasite prevalence was predicted \u2265 30%, including 6.4%, 12.1% and 6.3% of Kenya, mainland Tanzania and Uganda populations, respectively. Conversely, areas that supported very low parasite prevalence (&lt;1%) were inhabited by approximately 46.2 million people across the sub-region, or 52.2%, 26.7% and 10.4% of Kenya, mainland Tanzania and Uganda populations, respectively. In conclusion, parasite prevalence represents one of several data metrics for disease stratification at national and sub-national levels. To increase the use of this metric for decision making, there is a need to integrate other data layers on mortality related to malaria, malaria vector composition, insecticide resistance and bionomic, malaria care-seeking behaviour and current levels of unmet need of malaria interventions.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/ListItem\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.tropicalmedicine.ox.ac.uk/publications/1230569\" title=\"Maplaria: a user friendly web-application for spatio-temporal malaria prevalence mapping\" class=\"state-synced\">Maplaria: a user friendly web-application for spatio-temporal malaria prevalence mapping</a>\n            </h4>\n            \n            \n            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Abstract\nBackground\nModel-based geostatistical (MBG) methods have been extensively used to map malaria risk using community survey data in low-resource settings where disease registries are incomplete or non-existent. However, the wider adoption of MBG methods by national control programmes to inform health policy decisions is hindered by the lack of advanced statistical expertise and suitable computational equipment. Here, Maplaria, an interactive, user-friendly web-application that allows users to upload their own malaria prevalence data and carry out geostatistical prediction of annual malaria prevalence at any desired spatial scale, is introduced.\n\nMethods\nIn the design of the Maplaria web application, two main criteria were considered: the application should be able to classify subnational divisions into the most likely endemicity levels; the web application should allow only minimal input from the user in the set-up of the geostatistical inference process. To achieve this, the process of fitting and validating the geostatistical models is carried out by statistical experts using publicly available malaria survey data from the Harvard database. The stage of geostatistical prediction is entirely user-driven and allows the user to upload malaria data, as well as vector data that define the administrative boundaries for the generation of spatially aggregated inferences.\n\nResults\nThe process of data uploading and processing is split into a series of steps spread across screens through the progressive disclosure technique that prevents the user being immediately overwhelmed by the length of the form. Each of these is illustrated using a data set from the Malaria Indicator carried out in Tanzania in 2017 as an example.\n\nConclusions\nMaplaria application provides a user-friendly solution to the problem making geostatistical methods more accessible to users that have not undertaken formal training in statistics. The application is a useful tool that can be used to foster ownership, among policy makers, of disease risk maps and promote better use of data for decision-making in low resource settings.\n</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n"
    ], 
    "more": "\n\n    \n        <a href=\"https://www.tropicalmedicine.ox.ac.uk/news/act-on-acceptance-update/search?random=e8cdcee1-2662-421c-80e4-4f4c036863e3&amp;b_start:int=100&amp;format=json\" title=\"Load more\" class=\"btn btn-default load-more-button\">\n            Load More\n        </a>\n    \n\n", 
    "msg": ""
}